Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients

June 15, 2020

LAVAL, QC, June 15, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the recipients of the inaugural Salix Gastrointestinal Health Scholars Program. Ten outstanding students living with GI disease who are pursuing their higher education goals will each receive a \$10,000 scholarship award.

"At Salix, we understand the complexities of managing GI disease. We created the Salix Gastrointestinal Health Scholars Program to recognize students who are working diligently to achieve their higher educational goals while living with the challenges of a GI disease," said Robert Spurr, president, Salix. "We are inspired by the incredible resiliency and determination each of our winners has displayed in pursuit of their education."

The 2020 honorees were selected from more than 100 applications, based in part on essays sharing their experiences pursuing their education while living with a gastrointestinal condition. In their essays, applicants also shared the role their gastroenterologist, primary care physician or allied health care professional played in helping them reach their goals. The applications were reviewed by an independent panel of judges.

The Salix Gastrointestinal Health Scholars Program recognizes students across a wide range of educational pursuits, with scholarship awards in four categories, including the Undergraduate Scholar Awards for those pursuing undergraduate degrees; the Graduate Scholar Awards for those pursuing graduate degrees; the Working Parent's Scholar Award for working parents pursuing undergraduate, vocational/technical or graduate degrees; and the Single Parent's Scholar Award for single parents pursuing undergraduate, vocational/technical or graduate degrees.

The 2020 Salix Gastrointestinal Health Scholars Program recipients are:

Undergraduate Scholar Awards

- Jenny Peters, Smyrna, Tenn. The University of Alabama
- Julia Piligian, South Hadley, Mass. University of Massachusetts Lowell
- Kyla Sorensen, Seattle, Wash. Western Washington University
- Ryan Soto, Cibolo, Texas Trinity University

Graduate Scholar Awards

- Jakob Ozer, Needham, Mass. Boston University
- Jocelyn Perez, Revere, Mass. Columbia University
- Natacha Richemond, Atlanta, Ga. The George Washington University
- Samin Panahi, Bethesda, Md. University of Maryland

Working Parent's Scholar Award

• Audriana Duvall, Baltimore, Md. - The University of Baltimore

Single Parent's Scholar Award

• LaQuenta Baker, Helena, Ark. – Phillips Community College of the University of Arkansas To learn more about the Salix Gastrointestinal Health Scholars Program, visit www.Salix.com/Scholarship

. The 2021 Salix Gastrointestinal Health Scholars Program will begin accepting applications in November 2020.

About the Salix Gastrointestinal Health Scholars Program

The Salix Gastrointestinal Health Scholars Program, which is funded through the Bausch Foundation, is aimed at providing financial support to outstanding students who have not allowed GI disease to stand in the way of their academic achievements.

About the Bausch Foundation

The Bausch Foundation was established in 2017 to improve the lives of patients globally by providing access to safe, effective medicines and by financially supporting health care education and causes around the world. Since its inception, the Bausch Foundation has contributed millions of dollars' worth of financial and product donations to global charitable health organizations.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm healthcare providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, N.J.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

www.bauschhealth.com

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words

"anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch

Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

SAL.0098.USA.20 ©2020 Salix Pharmaceuticals or its affiliates.

Investor Contact:	Media Contact:
Arthur Shannon	Lainie Keller
arthur.shannon@bauschhealth.com	lainie.keller@bauschhealth.com
(514) 856-3855	908) 927-1198
(877) 281-6642 (toll free)	
	Karen Paff
	karen.paff@salix.com
	(908) 927-1190





C

View original content to download multimedia:

http://www.prnewswire.com/news-releases/salix-announces-inaugural-salix-gastrointestinal-healt h-scholars-program-recipients-301076570.html

SOURCE Bausch Health Companies Inc.





Investor Inquiries

<u>ir@bauschhealth.com</u> 877-281-6642 514-856-3855 (Canada)

Media inquiries

<u>Corporate.communications@bauschhealth.com</u> 908-569-3692

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

